Experiment ID: animal-model-comparison-001
Category: Animal Model Comparison
Priority: High — Critical evidence gap
Different preclinical animal models for Alzheimer's disease and Parkinson's disease recapitulate different aspects of human pathology, leading to inconsistent translation of therapeutic candidates to clinical success. A systematic head-to-head comparison of multiple models treated with identical therapeutic interventions will identify which models best predict human clinical outcomes.
The translational failure rate in neurodegenerative disease drug development exceeds 95% 1. A major contributor is the reliance on animal models that incompletely capture human disease pathology. Common models include:
No systematic comparison exists testing identical therapeutics across multiple models correlated with human tissue data.
Characterize baseline pathology across 6 AD models and 6 PD models using consistent histological, biochemical, and behavioral readouts.
Administer 3 established therapeutic candidates (anti-Aβ antibody, anti-tau ASO, GLP-1 agonist) across all models with identical dosing protocols.
Compare animal model responses to human brain bank data from corresponding therapeutic trials.
Alzheimer's Disease Models:
| Model | Background | Pathology | Source |
|---|---|---|---|
| APP/PS1 | C57BL/6 | Aβ plaques | Jackson Labs |
| 5xFAD | C57BL/6 | Aβ plaques, gliosis | Jackson Labs |
| 3xTG | 129/C57BL/6 | Aβ + tau | Jackson Labs |
| APPNL-G-F | C57BL/6 | Aβ plaques (humanized) | Jackson Labs |
| Tau P301S | C57BL/6 | Tau pathology | Jackson Labs |
| hTau | C57BL/6 | Human tau expression | Jackson Labs |
Parkinson's Disease Models:
| Model | Background | Pathology | Source |
|---|---|---|---|
| A53T α-syn | C57BL/6 | α-syn aggregation | Jackson Labs |
| MPTP-treated | C57BL/6 | DA neuron loss | Induced |
| 6-OHDA-treated | SD rats | DA neuron loss | Induced |
| LRRK2 G2019S tg | C57BL/6 | LRRK2 pathology | Jackson Labs |
| Pink1 knockout | C57BL/6 | Mitophagy deficits | Jackson Labs |
| α-syn preformed fibrils | C57BL/6 | Propagation model | Induced |
Histopathology:
Biochemical:
Behavioral:
Biomarkers (plasma):
-NfL, tau, Aβ42/40 ratio
Cohort 1 (3-month treatment):
Cohort 2 (6-month treatment):
| Item | Cost |
|---|---|
| APP/PS1 mice (100) | $12,000 |
| 5xFAD mice (100) | $12,000 |
| 3xTG mice (100) | $15,000 |
| A53T α-syn mice (100) | $18,000 |
| MPTP model (50) | $8,000 |
| Other models (200) | $30,000 |
| Subtotal | $95,000 |
| Item | Cost |
|---|---|
| Anti-Aβ antibody (10mg) | $25,000 |
| Anti-tau ASO (5mg) | $30,000 |
| GLP-1 agonist (liraglutide) | $8,000 |
| Vehicle/isotype controls | $5,000 |
| Subtotal | $68,000 |
| Role | Months | Cost |
|---|---|---|
| PI (25% effort) | 24 | $60,000 |
| Postdoc | 24 | $120,000 |
| Research associate | 24 | $96,000 |
| Veterinary staff | 12 | $36,000 |
| Subtotal | $312,000 |
| Item | Cost |
|---|---|
| Behavioral equipment | $40,000 |
| Histology supplies | $25,000 |
| ELISA/Western blot kits | $20,000 |
| Consumables | $30,000 |
| Subtotal | $115,000 |
| Item | Cost |
|---|---|
| Animal housing (24 months) | $72,000 |
| Human tissue acquisition | $40,000 |
| Data analysis software | $8,000 |
| Publication costs | $5,000 |
| Subtotal | $125,000 |
| Phase | Duration | Milestone |
|---|---|---|
| Phase 1 | Months 1-3 | Models characterized |
| Phase 2a | Months 4-9 | Cohort 1 complete |
| Phase 2b | Months 10-18 | Cohort 2 complete |
| Phase 3 | Months 15-24 | Human correlation complete |
| Analysis | Months 22-26 | Final analysis and publication |
Total: 26 months
| Dimension | Score (1-10) | Rationale |
|---|---|---|
| Scientific Value | 10 | Addresses fundamental translation gap |
| Feasibility | 8 | Well-established models, proven therapeutics |
| Novelty | 9 | First systematic cross-model comparison |
| Cost Efficiency | 8 | High impact per dollar — reduces future failures |
| Translation Potential | 10 | Direct impact on clinical trial design |
| Resource Requirements | 7 | Requires multiple model colonies |
| Risk Level | 6 | Some models may not respond to treatments |
| Generalizability | 9 | Findings applicable to all neurodegenerative diseases |
| Biomarker Potential | 8 | Identifies predictive biomarkers |
| Patient Relevance | 10 | Improves probability of clinical success |
Total Score: 85/100
This experiment should be followed by validation in non-human primates to confirm findings before clinical trial design.
Created: 2026-03-21 | Slot 1